ATE222928T1 - Humanisierte antikörper gegen cd38 - Google Patents

Humanisierte antikörper gegen cd38

Info

Publication number
ATE222928T1
ATE222928T1 AT95937133T AT95937133T ATE222928T1 AT E222928 T1 ATE222928 T1 AT E222928T1 AT 95937133 T AT95937133 T AT 95937133T AT 95937133 T AT95937133 T AT 95937133T AT E222928 T1 ATE222928 T1 AT E222928T1
Authority
AT
Austria
Prior art keywords
antibody
sequence
framework region
cdrs
amino acid
Prior art date
Application number
AT95937133T
Other languages
English (en)
Inventor
Jonathan Henry Ellis
Alan Peter Lewis
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Application granted granted Critical
Publication of ATE222928T1 publication Critical patent/ATE222928T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT95937133T 1994-12-02 1995-11-28 Humanisierte antikörper gegen cd38 ATE222928T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9424449A GB9424449D0 (en) 1994-12-02 1994-12-02 Antibodies
PCT/GB1995/002777 WO1996016990A1 (en) 1994-12-02 1995-11-28 Humanized antibodies to cd38

Publications (1)

Publication Number Publication Date
ATE222928T1 true ATE222928T1 (de) 2002-09-15

Family

ID=10765384

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95937133T ATE222928T1 (de) 1994-12-02 1995-11-28 Humanisierte antikörper gegen cd38

Country Status (9)

Country Link
US (1) US20050158305A1 (de)
EP (1) EP0794966B1 (de)
JP (1) JPH10509876A (de)
AT (1) ATE222928T1 (de)
AU (1) AU3933695A (de)
DE (1) DE69527975T2 (de)
ES (1) ES2181795T3 (de)
GB (1) GB9424449D0 (de)
WO (1) WO1996016990A1 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999055369A1 (en) * 1998-04-28 1999-11-04 Smithkline Beecham Corporation Monoclonal antibodies with reduced immunogenicity
EP1174440A1 (de) * 2000-07-19 2002-01-23 U-BISys B.V. Ein selektiv exprimiertes Epitop auf das menschliches CD38 Molekül detektiert von einem "phage display library"-derivierten menschlichen scFv Antikörperfragment
EP2990394A1 (de) 2001-11-30 2016-03-02 Biogen MA Inc. Antikörper gegen chemotaktische proteine
EP2322559A3 (de) 2002-07-04 2011-08-03 Patrys Limited Neoplasma-spezifische Antikörper und deren Verwendungen
AR040778A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
DE10311248A1 (de) 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
GB0306309D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
DE10353175A1 (de) 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
EP1531162A1 (de) 2003-11-14 2005-05-18 Heinz Vollmers Antikörper SAM-6, der spezifisch von Adenocarzinom ist, und dessen Verwendungen
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
EP2915820A1 (de) * 2004-02-06 2015-09-09 MorphoSys AG Humane Anti-CD38-Antikörper und Verwendungen davon
MXPA06008700A (es) 2004-02-06 2007-01-19 Morphosys Ag Anticuerpos anti-cd38 humanos y usos para los mismos.
EP2551282A3 (de) * 2005-03-23 2013-02-13 Genmab A/S Antikörper gegen CD38 zur Behandling von multiplem Myelom
TW200745162A (en) * 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
US7989595B2 (en) 2005-06-20 2011-08-02 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
USRE47223E1 (en) 2005-06-20 2019-02-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CN101287764B (zh) 2005-10-12 2013-11-13 莫佛塞斯公司 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
JP5328018B2 (ja) * 2006-06-05 2013-10-30 国立大学法人広島大学 抗ｃｄ３８抗体を細胞表面に有する免疫担当細胞
PL2081595T3 (pl) 2006-09-26 2019-11-29 Genmab As Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych
EP1914242A1 (de) * 2006-10-19 2008-04-23 Sanofi-Aventis Neue Antikörper gegen CD38 zur Behandlung von Krebs
PE20090245A1 (es) 2007-05-08 2009-03-17 Genentech Inc Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos
TW200944231A (en) 2007-11-30 2009-11-01 Glaxo Group Ltd Antigen-binding constructs
EP2401296A1 (de) 2009-02-24 2012-01-04 Glaxo Group Limited Multivalente und/oder multispezifische rankl-bindende konstrukte
CA2753287A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
US20110305693A1 (en) 2009-02-24 2011-12-15 Glaxo Group Limited Anitigen-binding constructs
WO2010115786A1 (en) 2009-04-01 2010-10-14 Glaxo Group Limited Anti-il-23 immunoglobulins
EP2421611A1 (de) 2009-04-24 2012-02-29 Glaxo Group Limited Fgfr1c-antikörper-kombinationen
EP2580243B1 (de) 2010-06-09 2019-10-16 Genmab A/S Antikörper gegen menschliches cd38
MX351887B (es) 2010-11-23 2017-11-01 Glaxo Group Ltd Proteinas de union a antigeno para oncostatina m (osm).
MX2013005847A (es) 2010-11-24 2013-12-12 Glaxo Group Ltd Proteinas de union a antigeno multiespecificas que eligen como blanco a hgf.
US8974782B2 (en) 2011-02-07 2015-03-10 Glaxo Group Limited Treatment of stroke comprising anti-MAG antibodies
EP2714737A1 (de) 2011-05-27 2014-04-09 Glaxo Group Limited Bcma (cd269/tnfrsf17)-bindende proteine
EP2888279A1 (de) 2012-08-22 2015-07-01 Glaxo Group Limited Anti-lrp6-antikörper
GB201216002D0 (en) 2012-09-07 2012-10-24 Deutsches Rheuma Forschungszentrum Berlin Drfz Compositions adn methods
RS60538B1 (sr) 2013-03-15 2020-08-31 Glaxosmithkline Ip Dev Ltd Anti-lag-3 vezujući proteini
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
WO2016040294A2 (en) 2014-09-09 2016-03-17 Janssen Biotech, Inc. Combination therapies with anti-cd38 antibodies
PE20171094A1 (es) 2014-12-04 2017-08-07 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
CR20170526A (es) 2015-05-20 2018-04-03 Janssen Biotech Inc ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
CN114656573B (zh) 2015-05-30 2024-09-27 分子模板公司 去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子
CN107708734B (zh) 2015-06-22 2022-01-11 詹森生物科技公司 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
RU2760582C2 (ru) 2015-09-02 2021-11-29 Иммутеп С.А.С. Анти-LAG-3 антитела
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
JP7027321B2 (ja) 2015-11-03 2022-03-01 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３８抗体の皮下製剤及びその使用
WO2018002181A1 (en) 2016-06-28 2018-01-04 Umc Utrecht Holding B.V. TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
US11618787B2 (en) 2017-10-31 2023-04-04 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
KR20220054579A (ko) * 2019-06-26 2022-05-03 더 존스 홉킨스 유니버시티 면역 효과기 세포의 표적화된 확장을 위한 방법 및 재료
CA3143211A1 (en) 2019-06-26 2020-12-30 Glaxosmithkline Intellectual Property Development Limited Il1rap binding proteins
BR112021026832A2 (pt) 2019-07-02 2022-05-10 Hutchinson Fred Cancer Res Vetores ad35 recombinantes e aprimoramentos da terapia gênica relacionada
CA3180690A1 (en) * 2020-06-17 2021-12-23 Ahmed Mahiuddin Cd38 antibodies for treatment of human diseases
AU2022218137A1 (en) 2021-02-03 2023-08-24 Mozart Therapeutics, Inc. Binding agents and methods of using the same
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
GB9221654D0 (en) * 1992-10-15 1992-11-25 Scotgen Ltd Recombinant human anti-cytomegalovirus antibodies
WO1994013805A1 (en) * 1992-12-10 1994-06-23 Celltech Limited Humanised antibodies directed against a33 antigen
AU6123894A (en) * 1993-01-29 1994-08-15 Board Of Trustees Of The Leland Stanford Junior University Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto

Also Published As

Publication number Publication date
US20050158305A1 (en) 2005-07-21
EP0794966A1 (de) 1997-09-17
WO1996016990A1 (en) 1996-06-06
AU3933695A (en) 1996-06-19
JPH10509876A (ja) 1998-09-29
GB9424449D0 (en) 1995-01-18
EP0794966B1 (de) 2002-08-28
DE69527975D1 (de) 2002-10-02
DE69527975T2 (de) 2003-03-27
ES2181795T3 (es) 2003-03-01

Similar Documents

Publication Publication Date Title
DE69527975D1 (de) Humanisierte antikörper gegen cd38
MXPA05003621A (es) Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos.
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
PL1654287T3 (pl) Kompozycje polipeptydów wiążących CD-20
DE69429095D1 (de) Humanisierte antikoerper
NZ324500A (en) Humanized antibodies to human gp39, compositions containing and therapeutic use thereof
TR200202254T2 (tr) IL-18 Kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri.
MY154009A (en) Anti-alpha v beta 6 antibodies
NZ529571A (en) Human antibodies that bind human IL-12 and methods for producing
NZ568769A (en) Human monoclonal antibodies against CD20
GB9619691D0 (en) Antibodies against E-selection
GR3026219T3 (en) Mouse monoclonal antibodies
DE69535319D1 (de) Rekombinante il-5 antagonisten für die behandlung von il-5 bedingten krankheiten
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
DE69125485D1 (de) Verfahren und zwischenprodukte synthetischer antikörperderivate
US20200131256A1 (en) Anti-pacap antibody
EP1411962A4 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
DE69922834D1 (de) Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation
DK0493446T3 (da) Behandling af autoimmunsygdom.
MXPA04001986A (es) Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.
NZ593171A (en) Monoclonal antibody SC104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent
DK0656906T3 (da) Endothelcellemolekyle, der medierer lymfocytbinding i mennesket
HUP0301085A2 (hu) Új peptid és alkalmazása szelektálási eljárásra
WO2023004036A3 (en) Anti-fsh antibodies for neurodegenerative diseases
UA93478C2 (ru) Выделенное моноклональное антитело человека, kotopoe связывается c cd20, и его применение

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties